Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML

Abstract excerpt

Monitoring of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) is predictive of disease recurrence and may identify patients who benefit from treatment intensification. Current MRD techniques rely on multicolor flow cytometry or molecular methods, but are limited in applicability or sensitivity. We evaluated the feasibility of a novel approach for MRD detection in peripheral blood...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Cancer Genomics and Diagnostics
• Share to Hematopoietic Stem Cell Transplantation